GPER1 and breast carcinoma: Synthetic selective and unselective GPER agonists (i.e., G-1, GPER-L1, GPER-L2, carbhydraz) and, as shown in Figure 1, antagonists (i.e., G-15, G-36, MIBE, C4PY, PBX1, PBX2) have been used to dissect the mechanisms governing GPER-mediated biological responses including those prompted in breast cancers [41,42,43,44,45,46,47,48].